Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

A. Jochems*, E. Bastiaannet, M.J.B. Aarts, A.C.J. van Akkooi, F.W.P.J. van den Berkmortel, M.J. Boers-Sonderen, A.J.M. van den Eertwegh, N.G. de Glas, J.W.B. de Groot, J.B.A.G. Haanen, G.A.P. Hospers, J.J.M. van der Hoeven, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, M.C.T. van Zeijl, E. KapiteijnM.W.J.M. Wouters

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1031-1038
Number of pages8
JournalJournal of Geriatric Oncology
Volume12
Issue number7
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • Metastatic melanoma
  • Older patients
  • Targeted therapy
  • Immune checkpoint inhibitors
  • Safety
  • Outcome
  • IMMUNE CHECKPOINT INHIBITORS
  • STAGE-III
  • DOUBLE-BLIND
  • IPILIMUMAB
  • IMMUNOTHERAPY
  • DABRAFENIB
  • NIVOLUMAB
  • AGE
  • MULTICENTER
  • VEMURAFENIB

Cite this